Hoth Therapeutics Plans To Test HT-003 API In Inflammatory Bowel Disorders; Shares Spike

Hoth Therapeutics Inc (NASDAQ: HOTH) plans to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis. The company has executed an option agreement with Isoprene Pharmaceuticals to investigate the potential.
In preclinical studies, the API of HT-003 has shown encouraging anti-inflammatory action and targets the retinoic acid metabolism pathway.
HT-003 can potentially inhibit the TLR2 signaling pathway, thus suggesting the effectiveness of this drug candidate not only for acne but in a broad range of diseases driven by overactive inflammatory responses to bacteria.
Hoth plans to investigate the therapeutic potential of the HT-003 API using relevant ex vivo tissue models and other in vitro molecular studies. This work will complement Hoth's current research activities investigating the therapeutic potential of HT-003 for the treatment of acne and psoriasis.
Price Action: HOTH gains 3.3% at $3.13 in premarket trading on last check Thursday.